公开(公告)号：WO2023057583A1

公开(公告)日：2023-04-13

申请号：PCT/EP2022/077836

申请日：2022-10-06

申请人： NORDIC NANOVECTOR ASA

发明人： GENERALOV, Roman ,  PASCAL, Veronique, Martine, Marie ,  HEYERDAHL, Helen ,  LLAMAZARES, Ada, Helena, Vilma, Repetto ,  ANDERSEN, Jan, Terje ,  FOSS, Stian ,  DAHLE, Jostein

IPC分类号： A61P35/00 ,  C07K16/28 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  C07K2317/94

摘要： The present disclosure relates to antibodies, antibody fragments and antibody derivates thereof and conjugates thereof and their use in immunotherapy and immunoconjugate therapy, including radioimmunotherapy of cancer with a humanized antibody with a high cytotoxicity as well as various applications of the antibodies.

公开(公告)号：WO2023288241A8

公开(公告)日：2023-01-19

申请号：PCT/US2022/073671

申请日：2022-07-13

申请人： GENENTECH, INC.

发明人： GAMPA, Gautham ,  HOSSEINI, Iraj ,  HUSENI, Mahrukh ,  KOERBER, James, Thomas ,  PAYANDEH, Jian, Mehr-dean ,  RUTZ, Sascha ,  SUN, Yonglian ,  CHIU, Cecilia, Pui Chi ,  DELFINO, Teresita, Arenzana

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.

公开(公告)号：WO2022266219A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033625

申请日：2022-06-15

申请人： XENCOR, INC.

发明人： BERNETT, Matthew, J. ,  MOORE, Gregory ,  NISTHAL, Alex

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73

摘要： The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Claudin18.2 (CLDN18.2).

公开(公告)号：WO2022256500A2

公开(公告)日：2022-12-08

申请号：PCT/US2022/031919

申请日：2022-06-02

申请人： HARPOON THERAPEUTICS, INC.

发明人： WESCHE, Holger ,  SUN, Liping

IPC分类号： C07K14/705 ,  A61P35/00 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

公开(公告)号：WO2022243261A1

公开(公告)日：2022-11-24

申请号：PCT/EP2022/063226

申请日：2022-05-17

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： DUERR, Harald ,  RAPP, Moritz ,  SUM, Eva Carina ,  TRUMPFHELLER, Christine ,  UMAÑA, Pablo

IPC分类号： A61P35/00 ,  A61K45/06 ,  C07K16/28 ,  C07K16/46 ,  C07K16/2878 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/75

摘要： The invention relates to new bispecific antigen binding molecules, comprising (a) at least two Fab fragments capable of specific binding to capable of specific binding to CD40, (b) Fc region composed of a first and a second subunit capable of stable association comprising one or more amino acid substitution that reduces the binding affinity of the antigen binding molecule to an Fc receptor and/or effector function and (c) one antigen binding domain capable of specific binding to carcinoembryonic antigen (CEA) connected to the C-terminus of the Fc region.

公开(公告)号：WO2022238977A2

公开(公告)日：2022-11-17

申请号：PCT/IB2022/054500

申请日：2022-05-13

申请人： ADIENNE S.A.

发明人： DI NARO, Antonio Francesco

IPC分类号： C07K16/28 ,  C07K16/40 ,  A61K39/00 ,  A61P17/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： This disclosure relates to methods of using an anti-CD26 antibody and antigen binding fragments thereof for the treatment of dermatomyositis.

公开(公告)号：WO2022238459A1

公开(公告)日：2022-11-17

申请号：PCT/EP2022/062731

申请日：2022-05-11

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE COTE D'AZUR

发明人： PAGES, Gilles

IPC分类号： C07K16/22 ,  A61P35/00 ,  A61P35/04 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76

摘要： The invention relates to a humanized monoclonal anti-vascular endothelial growth factor-C (VEGFC) antibody or a functional fragment thereof, comprising (i) the three heavy-chain CDRs of sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 under Kabat nomenclature, (ii) the three light-chain CDRs of sequences SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 under Kabat nomenclature, (iii) a heavy chain variable domain of sequence selected in the group consisting of SEQ ID NO: 15 or any sequence exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID NO: 13, and SEQ ID NO: 101 or any sequence exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID NO: 99, with the proviso that sequence SEQ ID NO: 4 is excluded and (iv) a light chain variable domain of sequence SEQ ID NO: 130 or any sequence exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID 128, with the proviso that SEQ ID NO:5 is excluded.

公开(公告)号：WO2022233770A1

公开(公告)日：2022-11-10

申请号：PCT/EP2022/061675

申请日：2022-05-02

申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH

发明人： WUCHERPFENNIG, Thomas ,  LIPPMANN, Rico

IPC分类号： C07K16/28 ,  C07K16/2866 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/41

摘要： The present invention relates to a method for producing the anti-IL36R antibody spesolimab. More specifically, the present invention relates to a method of producing spesolimab with a serum-free cell culture medium in a fed-batch culture in the presence of reduced copper and increased iron concentrations. In addition, the present invention relates to a composition comprising low levels of basic species of spesolimab and/or low levels of spesolimab species with high mannose structures.

公开(公告)号：WO2022233764A1

公开(公告)日：2022-11-10

申请号：PCT/EP2022/061661

申请日：2022-05-02

申请人： UCB BIOPHARMA SRL

发明人： LIGHTWOOD, Daniel John ,  KADIU, Irena ,  BHATTA, Pallavi ,  SPILIOTOPOULOS, Anastasios ,  ELLIOTT, Peter Charles ,  KEANEY, James Martin ,  DELKER, Silvia L. ,  ABENDROTH, Jan

IPC分类号： C07K16/28 ,  A61P25/28 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to antibodies binding to TREM1 and inhibiting its interaction with one or more of its natural ligands. Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such are also provided.

公开(公告)号：WO2022212836A1

公开(公告)日：2022-10-06

申请号：PCT/US2022/023041

申请日：2022-04-01

申请人： PYXIS ONCOLOGY, INC.

发明人： HERBST, Ronald ,  FELITSKY, Daniel ,  FENG, Jianwen ,  SEVERE, Nicolas ,  MILLER, Ona

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： The disclosure relates to immunoglobulins, or antigen-binding fragments thereof, that specifically bind to glycoprotein nonmetastatic melanoma protein B (GPNMB). Such immunoglobulins, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes, including treatment of cancers and to increase the effectiveness of vaccines.